Clinical monitoring | At baseline and at monthly intervals during treatment. | Canada [11], USA [12, 13], France [14], Portugal [15], Sweden [16], Ireland [17] |
Laboratory assessment at baseline# | Only recommended for individuals who are candidates for treatment aged >35 years. | Canada [11] |
Only recommended for individuals who are candidates for treatment with risk factors¶. | USA (CDC) [12] |
Only recommended for individuals who are candidates for treatment with risk factors+. | ATS (ATS) [13] |
Only recommended for individuals who are candidates for treatment aged >35 years and those with risk factors§. | Portugal [15] |
Suggested for individuals who are candidates for treatment aged >14 years.Recommended for all individuals who are candidates for treatment >35 years and for those with risk factorsƒ. | Ireland [17] |
Laboratory assessment during treatment# | In case of symptoms: if aged 35–50 years, systematic testing should occur once at completion at 1 month. Monthly testing for all those aged >50 years who have risk factors##. | Canada [11] |
In case of symptoms and for those with baseline abnormal values, otherwise monthly for those with risk factors¶. | USA (CDC) [12] |
In case of symptoms, or monthly for all those aged >35 years, those with abnormal baselines values for a liver function test, or those with risk factors+. | USA (ATS) [13] |
Every 2–4 weeks for those with HBeAG positivity. | USA (ATS) [13] |
Only recommended at 2 and 4 weeks after the start of therapy and monthly thereafter for those aged >65 years and those with risk factors¶¶. | France [14] |
Monthly for those aged >35 years or with risk factors§. | Portugal [15] |
Systematic testing of all those receiving treatment twice during the first month, monthly thereafter in adults and every second month in children. | Sweden [16] |
Some experts recommend testing every 2–4 weeks for the first 2–3 months of treatment. | Ireland [17] |